179 related articles for article (PubMed ID: 33123445)
1. Diabetic Ketoacidosis: An Adverse Reaction to Immunotherapy.
Keerty D; Das M; Hallanger-Johnson J; Haynes E
Cureus; 2020 Sep; 12(9):e10632. PubMed ID: 33123445
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
3. Diabetic Ketoacidosis as a Delayed Immune-Related Event after Discontinuation of Nivolumab.
Mae S; Kuriyama A; Tachibana H
J Emerg Med; 2021 Mar; 60(3):342-344. PubMed ID: 33097350
[TBL] [Abstract][Full Text] [Related]
4. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
Delasos L; Bazewicz C; Sliwinska A; Lia NL; Vredenburgh J
J Oncol Pharm Pract; 2021 Apr; 27(3):716-721. PubMed ID: 32723064
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report.
Porntharukchareon T; Tontivuthikul B; Sintawichai N; Srichomkwun P
J Med Case Rep; 2020 Sep; 14(1):171. PubMed ID: 32988414
[TBL] [Abstract][Full Text] [Related]
6. Diabetic ketoacidosis induced by nivolumab in invasive mucinous adenocarcinoma of the lung: a case report and review of the literature.
Yan J; Xie ZZ; Moran T; Gridelli C; Zheng MD; Dai SJ
Ann Transl Med; 2022 Nov; 10(22):1256. PubMed ID: 36544678
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy.
Alrifai T; Ali FS; Saleem S; Ruiz DCM; Rifai D; Younas S; Qureshi F
Case Rep Oncol Med; 2019; 2019():8781347. PubMed ID: 31781446
[TBL] [Abstract][Full Text] [Related]
8. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
Changizzadeh PN; Mukkamalla SKR; Armenio VA
J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
[TBL] [Abstract][Full Text] [Related]
9. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
Hakami OA; Ioana J; Ahmad S; Tun TK; Sreenan S; McDermott JH
Endocrinol Diabetes Metab Case Rep; 2019 Mar; 2019():. PubMed ID: 30836329
[TBL] [Abstract][Full Text] [Related]
10. Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism.
Patel S; Chin V; Greenfield JR
Endocrinol Diabetes Metab Case Rep; 2019 Dec; 2019():. PubMed ID: 31829972
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune Polyendocrinopathy Induced by an Antibody (KN046) That Simultaneously Inhibits PD-L1 and CTLA-4: A Case Report and Literature Review.
Li M; Wu C; Liu Y; Zhang R; Yang Q; Shi Z; Sun W; Hu X
Diabetes Metab Syndr Obes; 2022; 15():1253-1260. PubMed ID: 35494533
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis.
Tzoulis P; Corbett RW; Ponnampalam S; Baker E; Heaton D; Doulgeraki T; Stebbing J
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29576870
[TBL] [Abstract][Full Text] [Related]
13. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
14. A Severe Case of Diabetic Ketoacidosis and New-Onset Type 1 Diabetes Mellitus Associated with Anti-Glutamic Acid Decarboxylase Antibodies Following Immunotherapy with Pembrolizumab.
Kedzior SK; Jacknin G; Hudler A; Mueller SW; Kiser TH
Am J Case Rep; 2021 Jun; 22():e931702. PubMed ID: 34185763
[TBL] [Abstract][Full Text] [Related]
15. New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer.
Cunha C; Silva E; Vieira AC; Saraiva C; Duarte S
Endocrinol Diabetes Metab Case Rep; 2022 Feb; 2022():. PubMed ID: 35140188
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
Yilmaz M
J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
[TBL] [Abstract][Full Text] [Related]
17. Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic T-Lymphocyte-Associated Protein-4 Inhibitors): Results of a Retrospective Study.
Bajwa R; Cheema A; Khan T; Amirpour A; Paul A; Chaughtai S; Patel S; Patel T; Bramson J; Gupta V; Levitt M; Asif A; Hossain MA
J Clin Med Res; 2019 Apr; 11(4):225-236. PubMed ID: 30937112
[TBL] [Abstract][Full Text] [Related]
18. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
[TBL] [Abstract][Full Text] [Related]
19. Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab.
Cuenca JA; Laserna A; Reyes MP; Nates JL; Botz GH
Case Rep Crit Care; 2020; 2020():8671530. PubMed ID: 32274219
[TBL] [Abstract][Full Text] [Related]
20. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]